Let’s start up with the current stock price of AzurRx BioPharma Inc. (AZRX), which is $1.82 to be very precise. The Stock rose vividly during the last session to $2.0478 after opening rate of $2.00 while the lowest price it went was recorded $1.75 before closing at $1.69.
Recently in News on February 9, 2021, AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections. Phase 2 Study of oral niclosamide planned for 1H 2021. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
AzurRx BioPharma Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.6300 on 01/22/21, with the lowest value was $0.7900 for the same time period, recorded on 01/07/21.
AzurRx BioPharma Inc. (AZRX) full year performance was 92.63%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, AzurRx BioPharma Inc. shares are logging -30.80% during the 52-week period from high price, and 390.74% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.37 and $2.63.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 8614212 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the AzurRx BioPharma Inc. (AZRX) recorded performance in the market was 87.63%, having the revenues showcasing 151.38% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 70.20M, as it employees total of 10 workers.
Analysts verdict on AzurRx BioPharma Inc. (AZRX)
During the last month, 0 analysts gave the AzurRx BioPharma Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.9037, with a change in the price was noted +1.0249. In a similar fashion, AzurRx BioPharma Inc. posted a movement of +128.90% for the period of last 100 days, recording 4,512,283 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for AZRX is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
AzurRx BioPharma Inc. (AZRX): Technical Analysis
Raw Stochastic average of AzurRx BioPharma Inc. in the period of last 50 days is set at 57.37%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 54.73%. In the last 20 days, the company’s Stochastic %K was 47.35% and its Stochastic %D was recorded 43.68%.
Let’s take a glance in the erstwhile performances of AzurRx BioPharma Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 87.63%. Additionally, trading for the stock in the period of the last six months notably improved by 91.08%, alongside a boost of 92.63% for the period of the last 12 months. The shares increased approximately by 14.47% in the 7-day charts and went down by 121.95% in the period of the last 30 days. Common stock shares were driven by 151.38% during last recorded quarter.